Skip to main
INVA
INVA logo

Innoviva (INVA) Stock Forecast & Price Target

Innoviva (INVA) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 20%

Bulls say

Innoviva Inc has demonstrated strong financial performance, with year-over-year sales growth since the acquisition of key assets. Notably, Giapreza experienced a significant sales increase of 33% from 2023 to 2024, while Xerava has sustained annual sales growth exceeding 20% post-acquisition. Additionally, the annualized run rates for both Giapreza and Xerava have nearly doubled since Innoviva acquired them in August 2022, indicating successful integration and management of its strategic healthcare assets.

Bears say

Innoviva Inc. faces a challenging financial outlook as royalties from its key products, Relvar/Breo and Anoro, are projected to decline by an average of 8% and 4% year-over-year, respectively, over the next eight years. Additionally, the anticipated loss of exclusivity of Giapreza in 2034 further compounds the company's difficulties, as this could significantly impact revenue streams reliant on the product. Furthermore, the efficacy issues surrounding colistin against multi-drug-resistant strains may hinder potential growth in its critical care and infectious disease operating segments.

Innoviva (INVA) has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 20% predict a Strong Sell.

This aggregate rating is based on analysts' research of Innoviva and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Innoviva (INVA) Forecast

Analysts have given Innoviva (INVA) a Buy based on their latest research and market trends.

According to 5 analysts, Innoviva (INVA) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Innoviva (INVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.